From concept to practice: real-world safety of JAK inhibitors in rheumatoid arthritis treatment

Janus kinase inhibitors have emerged as highly effective therapies, gaining a prominent role in rheumatoid arthritis treatment. However, by inhibiting multiple cytokine effector pathways, these agents have also raised concerns regarding their safety profile. This article aims to provide an updated overview of the main safety aspects of JAK inhibitors, with a particular focus on their use in RA.